Details of the Drug

General Information of Drug (ID: DM1R5X4)

Drug Name
Becaplermin
Synonyms Regranex; Regranex (TN); Becaplermin (USAN/INN)
Indication
Disease Entry ICD 11 Status REF
Diabetic complication 5A2Y Approved [1]
Therapeutic Class
Antiulcer Agents
Affected Organisms
Humans and other mammals
ATC Code
A01AD08: Becaplermin
A01AD: Other agents for local oral treatment
A01A: STOMATOLOGICAL PREPARATIONS
A01: STOMATOLOGICAL PREPARATIONS
A: ALIMENTARY TRACT AND METABOLISM
D03AX06: Becaplermin
D03AX: Other cicatrizants
D03A: CICATRIZANTS
D03: PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS
D: DERMATOLOGICALS
Sequence
SLGSLTIAEPAMIAECKTRTEVFEISRRLIDRTNANFLVWPPCVEVQRCSGCCNNRNVQC
RPTQVQLRPVQVRKIEIVRKKPIFKKATVTLEDHLACKCETVAAARPVT
Cross-matching ID
UNII
1B56C968OA
DrugBank ID
DB00102
TTD ID
D0T5QT

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Platelet-derived growth factor receptor beta (PDGFRB) TTI7421 PGFRB_HUMAN Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Diabetic complication
ICD Disease Classification 5A2Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Platelet-derived growth factor receptor beta (PDGFRB) DTT PDGFRB 5.35E-10 0.36 0.89
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.